As tumours evolve, their surface and stromal protein expressions shift, demanding precision strategies in targeted radiopharmaceutical development. To ensure sustained therapeutic efficacy, it’s essential to choose radiopharmaceutical targets that reflect these dynamic changes, especially as we move beyond traditional oncogenic markers.

• Adapt TRP Targeting to Tumour Evolution: Track changes in tumour biology and adapt radiopharmaceutical targeting strategies accordingly
• Redefining What Makes a Good TRP Target: Focus on targets with strong tumour specificity, high expression density, and internalisation potential, as these are key attributes for radioligand efficacy
• Why HER2 and FAP are Leading Candidates: HER2 enables tumour-cell directed TRP approaches, while FAP provides access to the tumour stroma, broadening reach across solid tumours